CRISPR Therapeutics AG
CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programsā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$52.26
Price-2.23%
-$1.19
1Y
Price
Market Cap
$5.040b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1085.3%
EBITDA Margin-895.3%
Net Profit Margin-1901.1%
Free Cash Flow Margin-1085.3%
EBITDA Margin-895.3%
Net Profit Margin-1901.1%
Free Cash Flow MarginRevenue
$13.392m
+281.5%
1y CAGR+33.7%
3y CAGR+21215.9%
5y CAGREarnings
-$451.139m
+22.4%
1y CAGR-58.3%
3y CAGR-24.6%
5y CAGREPS
-$4.76
+26.4%
1y CAGR-48.8%
3y CAGR-17.4%
5y CAGRBook Value
$1.747b
$2.651b
Assets$904.219m
Liabilities$783.748m
DebtDebt to Assets
29.6%
-1.7x
Debt to EBITDAFree Cash Flow
-$480.726m
-39.0%
1y CAGR-43.9%
3y CAGR-20.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company